Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Niraparib (Primary)
- Indications Ovarian cancer
- Focus Expanded access; Therapeutic Use
- Sponsors TESARO
- 13 Apr 2017 Status changed from recruiting to completed.
- 19 Jan 2017 New trial record
- 17 Jan 2017 According to a Tesaro Inc. media release, an expanded access program for niraparib in Europe is planned to open in the first half of 2017, and will be initiated on a country-by-country basis.